Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23843234 | 0.91 | KLKB1 (0.35) | KLKB1SMN1; SMN2TDP1POLBFAAH | |
| SCHEMBL23754027 | 0.90 | KLKB1 (0.45) | KLKB1SMN1; SMN2TDP1POLB | |
| SCHEMBL23769398 | 0.84 | KLKB1 (0.41) | KLKB1SMN1; SMN2TDP1POLBMAPT | |
| SCHEMBL23843236 | 0.81 | KLKB1 (0.45) | KLKB1TDP1 | |
| SCHEMBL23769709 | 0.78 | KLKB1 (0.37) | KLKB1SMN1; SMN2TDP1POLBCCR4 | |
| SCHEMBL23843119 | 0.78 | KLKB1 (0.40) | KLKB1SMN1; SMN2TDP1POLBMAPT | |
| SCHEMBL23843038 | 0.78 | KLKB1 (0.40) | KLKB1SMN1; SMN2TDP1POLBFAAH | |
| SCHEMBL23769711 | 0.76 | KLKB1 (0.38) | KLKB1SMN1; SMN2MAPTCCR4FAAH | |
| SCHEMBL23769710 | 0.76 | FAAH (0.35) | KLKB1SMN1; SMN2TDP1POLBCCR4 | |
| SCHEMBL23769712 | 0.74 | KLKB1 (0.34) | KLKB1SMN1; SMN2MAPTCCR4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885SMN1; SMN2 4693/4885TDP1 2205/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885SMN1; SMN2 4693/4885TDP1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.